Loading clinical trials…
Loading clinical trials…
Clinical trials · failure tracking
Oncology studies whose overall status is TERMINATED, WITHDRAWN or SUSPENDED on ClinicalTrials.gov, with the stop reason exactly as the registrant posted it. A category is attached only when an explicit keyword rule matches the text; CancerIndex never infers why a study stopped.
547 stopped studies mapped to Malignant Nervous System Neoplasm and descendants · 90% state a reason
Over the 547 studies matching the cancer, status and year filters (the category filter does not change this chart). Each study is counted once, in the first matching category; greyed bars are studies whose text matched no rule or was empty.
Computedrules ci-stop-reasons-v1 · keyword matching only
A category is assigned when one of its keywords appears in the posted text (case-insensitive, whole words). Rules are tested in this order and the first match wins; every match is kept in the API (reasonMatches).
| NCT | Title | Phase | Status | First posted | Lead sponsor | Why stopped (as posted) | Category |
|---|---|---|---|---|---|---|---|
| NCT01440283 | A Phase II Study of Intensity Modulated Radiation Therapy (IMRT) in High Risk Abdominal… | Phase 2 | terminated | Sep 26, 2011 | St. Jude Children's Research Hospital | not stated | Not stated |
| NCT01756729 | Post-approval Study of NovoTTF-100A in Recurrent GBM Patients | Phase 4 | terminated | Dec 27, 2012 | NovoCure Ltd. | Amendment of Study Protocol | Other (stated, no rule matched) |
| NCT00703859 | Combining Radiotherapy and Temozolomide With Dichloroacetate in Patients With Newly… | Phase 1 | withdrawn | Jun 24, 2008 | AHS Cancer Control Alberta | not stated | Not stated |
| NCT01954030 | Phase 1/2 CTO + Bevacizumab for Recurrent Glioma Post-Bevacizumab Failure | Phase 1 | terminated | Oct 1, 2013 | Annick Desjardins | Study terminated early due to funding reasons prior to completing Phase 1 | Funding |
| NCT02521090 | EGFRBi-Armed Autologous T Cells in Treating Patients With Recurrent or Refractory… | Phase 1 / Phase 2 | withdrawn | Aug 13, 2015 | Barbara Ann Karmanos Cancer Institute | Due to lack of funding and a primary co-investigator of the trial leaving the institution. | Investigator |
| NCT01189240 | RO4929097and Bevacizumab in Treating Patients With Progressive or Recurrent Malignant… | Phase 1 / Phase 2 | terminated | Aug 26, 2010 | National Cancer Institute (NCI) | Company decided to stop development of drug - 7/31/12 | Sponsor / business decision |
| NCT01260467 | Memantine for Recurrent Glioblastoma | Phase 2 | terminated | Dec 15, 2010 | University of Rochester | not stated | Not stated |
| NCT00003273 | Chemotherapy Followed by Peripheral Stem Cell Transplantation in Treating Children With… | Phase 2 | withdrawn | Jan 27, 2003 | NYU Langone Health | not stated | Not stated |
| NCT00992173 | Efficacy and Safety of Ultratrace™ Iobenguane I 131 in Neuroblastoma | Phase 2 | withdrawn | Oct 9, 2009 | Molecular Insight Pharmaceuticals, Inc. | not stated | Not stated |
| NCT02599090 | Phase II Sorafenib With Radiation and Temozolomide in Newly Diagnosed Glioblastoma or… | Phase 2 | withdrawn | Nov 6, 2015 | M.D. Anderson Cancer Center | Multi phase study did not progress to Phase II. Phase I registered as NCT00734526. | Other (stated, no rule matched) |
| NCT00874315 | Allogeneic Hematopoietic Stem Cell Transplantation for Relapsed or Refractory High-Risk… | Phase 2 | withdrawn | Apr 2, 2009 | Nationwide Children's Hospital | lack of accrual | Enrollment / accrual |
| NCT01778530 | TRC105 for Recurrent Glioblastoma | Phase 2 | terminated | Jan 29, 2013 | National Cancer Institute (NCI) | Study was terminated due to poor accrual. | Enrollment / accrual |
| NCT00923117 | Sunitinib to Treat Recurrent Brain Cancer | Phase 2 | terminated | Jun 18, 2009 | National Cancer Institute (NCI) | The study was terminated based on results of an interim analysis for futility. | Efficacy / futility |
| NCT01898273 | Imaging Trial With I-124-CLR1404 in Patients With Newly Diagnosed or Recurrent… | Phase 2 | terminated | Jul 12, 2013 | Cellectar Biosciences, Inc. | not stated | Not stated |
| NCT01558960 | Intravitreal Injections of Melphalan for Retinoblastoma | N/A | terminated | Mar 20, 2012 | Hadassah Medical Organization | Sufficient findings to draw conclusions | Other (stated, no rule matched) |
| NCT01227434 | A Study of PD 0332991 in Patients With Recurrent Rb Positive Glioblastoma(PD0332991) | Phase 2 | terminated | Oct 25, 2010 | University of California, San Francisco | not stated | Not stated |
| NCT01174537 | New Castle Disease Virus (NDV) in Glioblastoma Multiforme (GBM), Sarcoma and Neuroblastoma | Phase 1 / Phase 2 | withdrawn | Aug 3, 2010 | Hadassah Medical Organization | not stated | Not stated |
| NCT01861990 | Valproic Acid in Childhood Progressive Brain Tumors | Phase 1 | withdrawn | May 24, 2013 | Medical University of South Carolina | Feasibility of the trial was proven to be absent. | Other (stated, no rule matched) |
| NCT01711580 | Re-irradiation of High Grade Gliomas: a Quality of Life Study | — | withdrawn | Oct 22, 2012 | Maastricht Radiation Oncology | Another study was commenced for this patient group | Other (stated, no rule matched) |
| NCT01122888 | Cilengitide and Sunitinib Malate in Treating Patients With Advanced Solid Tumors or… | Phase 1 | terminated | May 13, 2010 | National Cancer Institute (NCI) | not stated | Not stated |
| NCT01317212 | Dose-Escalation Study of Carboplatin Administration Into the Brain for Glioblastoma… | Phase 1 | withdrawn | Mar 17, 2011 | North Bristol NHS Trust | Sufficient funding could not be secured for the study | Funding |
| NCT01100658 | Effects of Methylphenidate on Attention Deficits in Childhood Cancer Survivors | N/A | terminated | Apr 9, 2010 | University of Minnesota | Due to slow accrual | Enrollment / accrual |
| NCT01225510 | A Trial Of PF-04856884 In Patients With Recurrent Glioblastoma | Phase 2 | withdrawn | Oct 21, 2010 | Pfizer | not stated | Not stated |
| NCT00432445 | Proton Beam Radiation Therapy for Intraocular and Periocular Retinoblastoma | Phase 2 | terminated | Feb 7, 2007 | M.D. Anderson Cancer Center | Low accrual. | Enrollment / accrual |
| NCT02128373 | A Computer-Based Intervention for Distance Caregivers of Parents With Advanced Cancer | N/A | terminated | May 1, 2014 | Case Comprehensive Cancer Center | Slow Accrual | Enrollment / accrual |
| NCT01795430 | Whole-Body Radiation Therapy, Systemic Chemotherapy, and High-Dose Chemotherapy Followed… | N/A | withdrawn | Feb 20, 2013 | City of Hope Medical Center | No participants enrolled. | Enrollment / accrual |
| NCT01378481 | High-Dose Vorinostat and Fractionated Stereotactic Body Radiation Therapy in Treating… | Phase 1 | terminated | Jun 22, 2011 | National Cancer Institute (NCI) | not stated | Not stated |
| NCT00624962 | Early Enteral Tube Feedings in Children Receiving Chemo for AML/MDS & High Risk Solid… | N/A | withdrawn | Feb 28, 2008 | Vanderbilt University | no participants enrolled | Enrollment / accrual |
| NCT01077440 | Presence of Donor-Derived DNA in Semen Samples From Cancer Survivors Who Underwent Donor… | — | terminated | Mar 1, 2010 | Vanderbilt University | PI leaving institution | Other (stated, no rule matched) |
| NCT01404702 | Pilot Study of Zoledronic Acid and Interleukin-2 for Refractory Pediatric Neuroblastoma | Phase 1 | terminated | Jul 28, 2011 | University of Alabama at Birmingham | Accrual slower than anticipated | Enrollment / accrual |
| NCT00761280 | Efficacy and Safety of AP 12009 in Patients With Recurrent or Refractory Anaplastic…(SAPPHIRE) | Phase 3 | terminated | Sep 29, 2008 | Isarna Therapeutics GmbH | Unable to recruit the projected patient number. All analyses are descriptive, only. | Enrollment / accrual |
| NCT00378235 | Phase I/II Trial of Intracerebral IL13-PE38QQR Infusions in Pediatric Patients With… | Phase 1 / Phase 2 | withdrawn | Sep 19, 2006 | INSYS Therapeutics Inc | There was a change of sponsor. The new sponsor company did not wish to conduct the study after all. | Sponsor / business decision |
| NCT01088763 | Gamma-Secretase Inhibitor RO4929097 in Treating Young Patients With Relapsed or… | Phase 1 | terminated | Mar 17, 2010 | National Cancer Institute (NCI) | not stated | Not stated |
| NCT01320787 | 18-F-Fluoroacetate as PET Imaging Agent | Phase 1 | withdrawn | Mar 22, 2011 | M.D. Anderson Cancer Center | not stated | Not stated |
| NCT01952886 | Patient Satisfaction, Efficacy and Compliance of Antiemetic Patch vs Pill in Malignant… | Phase 2 | withdrawn | Sep 30, 2013 | Duke University | Lack of approval and funding from company | Funding |
| NCT00589095 | Early Detection of Glioblastoma Multiforme (GBM) Treatment Responses Using Multiple… | — | terminated | Jan 9, 2008 | Yale University | not stated | Not stated |
| NCT02055196 | Genetically Modified Stem Cells and Irinotecan Hydrochloride in Treating Patients With… | Phase 1 | withdrawn | Feb 5, 2014 | City of Hope Medical Center | New study written | Other (stated, no rule matched) |
| NCT00387426 | Sunitinib in Treating Patients With Idiopathic Myelofibrosis | Phase 2 | terminated | Oct 13, 2006 | National Cancer Institute (NCI) | not stated | Not stated |
| NCT01515085 | MRI-Guided Laser Induced Thermal Therapy(LITT) | — | terminated | Jan 23, 2012 | Rutgers, The State University of New Jersey | PI elected to close study | Other (stated, no rule matched) |
| NCT01169415 | Effects of Steroid Tapering on Functional Capacity and Neurocognition | N/A | withdrawn | Jul 26, 2010 | Duke University | Funding not obtained | Funding |
| NCT01403285 | Peptide-based Glioma Vaccine IMA950 in Patients With Glioblastoma | Phase 1 | terminated | Jul 27, 2011 | Immatics Biotechnologies GmbH | Due to poor accrual. This decision was taken without any safety reasons. Since beginning of the… | Safety / toxicity |
| NCT00636805 | Aloxi for Prevention of Chemotherapy Induced Nausea and Vomiting in Malignant Glioma… | Phase 2 | terminated | Mar 14, 2008 | Duke University | Study was halted early after 63 subjects were enrolled due to slow accrual. | Enrollment / accrual |
| NCT01854099 | Peptide Vaccine for Glioblastoma Against Cytomegalovirus Antigens(PERFORMANCE) | Phase 1 | withdrawn | May 15, 2013 | University of Florida | Investigator decided not to open study. | Investigator |
| NCT01400958 | Nuvigil or Placebo in Newly Diagnosed Malignant Glioma | Phase 2 | terminated | Jul 25, 2011 | H. Lee Moffitt Cancer Center and Research Institute | Slow Accrual, Initiating Principal Investigator (PI) left Moffitt | Investigator |
| NCT01319838 | Aflac ST1001 Prolonged Isotretinoin(Aflac ST1001) | Phase 1 | withdrawn | Mar 22, 2011 | Emory University | no patient enrollment | Enrollment / accrual |
| NCT00003292 | S9624 Ifosfamide in Treating Patients With Meningeal Tumors | Phase 2 | terminated | Jan 27, 2003 | SWOG Cancer Research Network | lack of accrual | Enrollment / accrual |
| NCT01652768 | PRESENCE Project: An Early Palliative Care Intervention in Brain Tumors | N/A | terminated | Jul 30, 2012 | Case Comprehensive Cancer Center | Research Cancelled | Other (stated, no rule matched) |
| NCT01697514 | A Study of LY2940680 in Pediatric Medulloblastoma or Rhabdomyosarcoma | Phase 1 | withdrawn | Oct 2, 2012 | Eli Lilly and Company | Trial stopped early for poor accrual. | Enrollment / accrual |
| NCT01205334 | Administration of CMV-Specific Cytotoxic T Cells in Patients With Glioblastoma Multiforme(COGLI) | Phase 1 / Phase 2 | terminated | Sep 20, 2010 | Baylor College of Medicine | poor accrual | Enrollment / accrual |
| NCT00003505 | Antineoplaston Therapy in Treating Patients With Primary Central Nervous System Lymphoma | Phase 2 | withdrawn | Jan 27, 2003 | Burzynski Research Institute | not stated | Not stated |
Stop reasons are registrant-reported free text and are displayed verbatim (truncated; hover for the full text). Categories come from explicit keyword rules and are never inferred from the study design, sponsor or outcome; a study that stopped for several reasons is filed under the first rule that matched. A TERMINATED status does not imply a negative result.
Data updated 23 days agoSource updated Mar 3, 2016source: clinicaltrials